Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
CDKN2B-AS
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
miR-125a-5p-Bcl2/MRP4 pathway
Cancer name
Endometrial Cancer
Cancer site
Corpus Uteri
Treatment type
Chemotherapy
Drug
Paclitaxel
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Down
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Up
Number of patients
87
Male patients
Not available
Female patients
Not available
Age range and number
44(<=54)+43(>54)
PMID
Description
High-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients.
Tissue resource
paracancerous normal endometrium tissue and endometrial cancer tissue specimens
human endometrial cancer cell lines HEC-251
human endometrial cancer cell lines HEC-1A
human embryonic kidney cell lines HEK293T
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Shengjing Hospital of China Medical University
the Cell Resource Center of Chinese Academy of Medical Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.